论文部分内容阅读
目的用原位杂交方法观察生长抑素受体在甲状腺肿瘤组织及癌旁组织中的表达。方法根据生长抑素受体(SSTR)亚型的基因结构设计两种cDNA探针:针对各型生长抑素受体的寡核苷酸探针以及特异性针对二型生长抑素受体(SSTR2)的寡核苷酸探针序列,并分别与各型甲状腺肿瘤组织及癌旁组织行原位杂交,采用Mias图像分析仪进行灰度分析,mRNA丰度以信号强度x-±s表示,进行t检验。结果甲状腺髓样癌组织中SSTR的表达明显高于癌周组织(P<0.05),SSTR2仅在癌组织中有表达。SSTR在甲状腺乳突状癌组织中的表达明显高于癌周组织(P<0.05),SSTR2在癌组织及癌周组织内均未见有表达。滤泡性腺癌组织SSTR的表达明显高于癌周组织(P<0.05),癌组织及癌周组织均未见有SSTR2表达。嗜酸性细胞癌组织SSTR的表达明显高于癌周组织(P<0.05),SSTR2仅在癌组织中有表达。结论SSTR2仅在MTC及HCC的肿瘤组织中有表达;各型甲状腺肿瘤组织均表达除SSTR2之外的其他几型SSTR中的一种或数种,且肿瘤组织中的表达强度明显高于邻近正常组织。某些靶向生长抑素受体(尤其是特异性靶向SSTR2)的化合物(配体),可能成为甲状腺肿瘤尤其是甲状腺髓样癌和嗜酸性细胞癌的特异性显像剂和靶向治疗载体。
Objective To observe the expression of somatostatin receptor in thyroid tumor tissues and adjacent tissues by in situ hybridization. Methods Two cDNA probes were designed according to the gene structure of the somatostatin receptor (SSTR) subtype: oligonucleotide probes targeting all kinds of somatostatin receptors, and specific probes targeting somatostatin type 2 (SSTR2 ) Oligonucleotide probe sequence, and each type of thyroid tumor tissue and adjacent tissues in situ hybridization using Mias image analyzer for grayscale analysis, mRNA abundance signal intensity x- ± s said, carried out t test. Results The expression of SSTR in medullary thyroid carcinoma was significantly higher than that in peri-cancerous tissues (P <0.05). SSTR2 was only expressed in cancerous tissues. The expression of SSTR in thyroid papillary carcinoma tissues was significantly higher than that in peritumoral tissues (P <0.05). SSTR2 expression was not found in both cancerous tissues and peritumoral tissues. The expression of SSTR in follicular adenocarcinoma was significantly higher than that in peritumorous tissues (P <0.05). No SSTR2 expression was found in cancerous and peritumoral tissues. The expression of SSTR in eosinophilic carcinoma was significantly higher than that in peri-cancerous tissues (P <0.05). SSTR2 was only expressed in cancerous tissues. Conclusions SSTR2 is only expressed in the tumor tissues of MTC and HCC. Each type of thyroid tumor expresses one or more of several types of SSTR except SSTR2, and the expression intensity in tumor tissues is significantly higher than that in adjacent normal organization. Certain compounds (ligands) that target somatostatin receptors, specifically specifically targeting SSTR2, may be specific imaging agents and targeted therapies for thyroid tumors, especially medullary thyroid carcinoma and eosinophilic carcinoma Vector.